San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Lee, J C ^a   Tseng, C K ^a   Wu, S F ^a   Chang, F R ^a   Chiu, C C ^a   Wu, Y C ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cyclooxygenase 2; hepatitis C virus; nuclear factor kB; San Huang Xie Xin Tang; synergistic

Indexed keywords

2' METHYLCYTIDINE; ALPHA INTERFERON; CYCLOOXYGENASE 2; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTRUCTURAL PROTEIN 5A; RECOMBINANT ALPHA2A INTERFERON; SAN HUANG XIE XIN TANG EXTRACT; TELAPREVIR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG POTENTIATION; DRUG SELECTIVITY; HEPATITIS C VIRUS; HEPATOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; CATECHIN; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTIDINE; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; NF-KAPPA B; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 79959605633     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01424.x     Document Type: Article

References (50)

1. Alter MJ,. Epidemiology of hepatitis C. Hepatology 1997; 26 (3 Suppl. 1): 62S-65S. (Pubitemid 27388074)
2. Kenny-Walsh E,. The natural history of hepatitis C virus infection. Clin Liver Dis 2001; 5 (4): 969-977. (Pubitemid 33001015)
3. Lindenbach BD, Rice CM,. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436 (7053): 933-938. (Pubitemid 41191668)
4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM,. Structural biology of hepatitis C virus. Hepatology 2004; 39 (1): 5-19. (Pubitemid 38461460)
5. Lu L, Wei L, Peng G, et al. NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. Virology 2008; 371 (1): 61-70.
6. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53 (11): 1665-1672. (Pubitemid 39434113)
7. Waris G, Siddiqui A,. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005; 79 (15): 9725-9734. (Pubitemid 41022315)
8. Giannitrapani L, Ingrao S, Soresi M, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci 2009; 1155: 293-299.
9. Kanda T, Yokosuka O, Nagao K, Saisho H,. State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X. Cancer Lett 2006; 234 (2): 143-148.
10. Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008; 47 (5): 1462-1472. (Pubitemid 351702730)
11. Lo YC, Tsai PL, Huang YB, et al. San-Huang-Xie-Xin-Tang reduces lipopolysaccharides-induced hypotension and inflammatory mediators. J Ethnopharmacol 2005; 96 (1-2): 99-106.
12. Lo YC, Lin YL, Yu KL, et al. San-Huang-Xie-Xin-Tang attenuates inflammatory responses in lipopolysaccharide-exposed rat lungs. J Ethnopharmacol 2005; 101 (1-3): 68-74. (Pubitemid 41265603)
13. Shih YT, Wu DC, Liu CM, Yang YC, Chen IJ, Lo YC,. San-Huang-Xie-Xin-Tang inhibits Helicobacter pylori-induced inflammation in human gastric epithelial AGS cells. J Ethnopharmacol 2007; 112 (3): 537-544.
14. Tsai HH, Chen IJ, Lo YC,. Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure. J Ethnopharmacol 2008; 117 (3): 457-462.
15. Lin WC, Tan TW,. The role of gastric muscle relaxation in cytoprotection induced by san-huang-xie-xin-tang in rats. J Ethnopharmacol 1994; 44 (3): 171-179.
16. Shia CS, Hou YC, Juang SH, et al. Metabolism and pharmacokinetics of San-Huang-Xie-Xin-Tang, a polyphenol-rich chinese medicine formula, in rats and ex-vivo antioxidant activity. Evid Based Complement Alternat Med 2009; doi:.
17. Shih YT, Chen IJ, Wu YC, Lo YC,. San-Huang-Xie-Xin-Tang protects against activated microglia- and 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Evid Based Complement Alternat Med 2009; doi:.
18. Li CY, Hou YC, Lee Chao PD, Shia CS, Hsu IC, Fang SH,. Potential ex vivo immunomodulatory effects of San-Huang-Xie-Xin-Tang and its component herbs on mice and humans. J Ethnopharmacol 2010; 127 (2): 292-298.
19. Chen HC, Hsieh MT,. Two-year experience with "San-Huang-Hsieh-Hsin- Tang" in essential hypertension. Am J Chin Med 1986; 14 (1-2): 51-58.
20. Chen HC, Hsieh MT,. Hemodynamic effects of "san-huang-hsieh-hsin- tang" in patients with essential hypertension. Am J Chin Med 1986; 14 (3-4): 153-156.
21. Zhang L, Yang L, Zheng X,. A study of Helicobacterium pylori and prevention and treatment of chronic atrophic gastritis. J Tradit Chin Med 1997; 17 (1): 3-9.
22. Cheng WY, Wu SL, Hsiang CY, et al. Relationship Between San-Huang-Xie-Xin-Tang and its herbal components on the gene expression profiles in HepG2 cells. Am J Chin Med 2008; 36 (4): 783-797.
23. Hu JZ, Bai L, Chen DG, Xu QT, Southerland WM,. Computational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder. Interdiscip Sci 2010; 2 (2): 151-156.
24. Xu G, Dou J, Zhang L, Guo Q, Zhou C,. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol Pharm Bull 2010; 33 (2): 238-243.
25. Cheng Y, Ping J, Xu HD, Fu HJ, Zhou ZH,. Synergistic effect of a novel oxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro. World J Gastroenterol 2006; 12 (32): 5153-5159. (Pubitemid 44355911)
26. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004; 31 (1): 69-75. (Pubitemid 39024388)
27. Guo Q, Zhao L, You Q, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res 2007; 74 (1): 16-24. (Pubitemid 46366014)
28. Ma SC, Du J, But PP, et al. Antiviral Chinese medicinal herbs against respiratory syncytial virus. J Ethnopharmacol 2002; 79 (2): 205-211. (Pubitemid 34136952)
29. Blight KJ, Kolykhalov AA, Rice CM,. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290 (5498): 1972-1974.
30. Tazawa R, Xu XM, Wu KK, Wang LH,. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994; 203 (1): 190-199. (Pubitemid 24281079)
31. Lee JC, Shih YF, Hsu SP, Chang TY, Chen LH, Hsu JT,. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal Biochem 2003; 316 (2): 162-170. (Pubitemid 36444545)
32. Lee JC, Tseng CK, Chen KJ, Huang KJ, Lin CK, Lin YT,. A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal Biochem 2010; 403 (1-2): 52-62.
33. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11 (7): 791-796. (Pubitemid 41021213)
34. Bassit L, Grier J, Bennett M, Schinazi RF,. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother 2008; 19 (1): 25-31.
35. Lin K, Perni RB, Kwong AD, Lin C,. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006; 50 (5): 1813-1822.
36. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
37. Tallarida RJ,. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298 (3): 865-872. (Pubitemid 32761897)
38. Mann EA, Stanford S, Sherman KE,. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation. Virus Res 2006; 121 (1): 51-57. (Pubitemid 43994212)
39. Kasprzak A, Adamek A,. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008; 38 (1): 1-26. (Pubitemid 350182573)
40. Li S, Kodama EN, Inoue Y, et al. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication. Antivir Chem Chemother 2010; 20 (6): 239-248.
41. Takeshita M, Ishida Y, Akamatsu E, et al. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem 2009; 284 (32): 21165-21176.
42. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50 (3): 899-909. (Pubitemid 43327793)
43. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (2): 447-462.
44. Trujillo-Murillo K, Alvarez-Martinez O, Garza-Rodriguez L, et al. Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J Viral Hepat 2007; 14 (9): 608-617. (Pubitemid 47258261)
45. Gretton S, Hughes M, Harris M,. Hepatitis C virus RNA replication is regulated by Ras-Erk signalling. J Gen Virol 2010; 91 (Pt 3): 671-680.
46. Okamoto M, Sakai M, Goto Y, et al. Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir Chem Chemother 2009; 20 (1): 47-54.
47. Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE,. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA 2002; 99 (6): 3932-3937. (Pubitemid 34252208)
48. Reynolds AE, Enquist LW,. Biological interactions between herpesviruses and cyclooxygenase enzymes. Rev Med Virol 2006; 16 (6): 393-403. (Pubitemid 44763840)
49. Liu T, Zaman W, Kaphalia BS, Ansari GA, Garofalo RP, Casola A,. RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. Virology 2005; 343 (1): 12-24. (Pubitemid 41572230)
50. Tung WH, Hsieh HL, Yang CM,. Enterovirus 71 induces COX-2 expression via MAPKs, NF-kappaB, and AP-1 in SK-N-SH cells: role of PGE(2) in viral replication. Cell Signal 2010; 22 (2): 234-246.